Table 1.
CL | NUCL | MCL | VL | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
IT n (%) | PR n (%) | HN | IT n (%) | PR n (%) | HN | IT n (%) | PR n (%) | HN | IT n (%) | PR n (%) | HN | |
2009 | 0 | 23 (4.4) | 525 | 43 (4.5) | 771 (81.5) | 946 | 0 | 0 | 4 | 0 | 2 (100) | 2 |
2010 | 0 | 5 (0.6) | 771 | 18 (3.6) | 491 (98.6) | 498 | 0 | 0 | 3 | 0 | 9 (100) | 9 |
2011 | 0 | 0 | 1546 | 22 (5.9) | 260 (70.0) | 371 | 0 | 0 | 13 | 0 | 5 (83.3) | 6 |
2012 | 12 (1.14) | 18 (1.7) | 1056 | 95 (10.8) | 673 (76.7) | 877 | 0 | 0 | 2 | 0 | 0 | 0 |
2013 | 0 | 1 | 1316 | 93 (12.2) | 491 (64.6) | 760 | 0 | 0 | 3 | 0 | 3 (100) | 3 |
2014 | 3 (0.32) | 3 (0.3) | 935 | 214 (22.5) | 778 (81.9) | 950 | 0 | 0 | 14 | 1 (50.0) | 2 (100) | 2 |
2015 | 0 | 0 | 1039 | 89 (9.1) | 723 (73.6) | 982 | 0 | 0 | 27 | 0 | 5 (83.3) | 6 |
Abbreviations: CL cutaneous, NUCL non-ulcerative, MCL muco-cutaneous, VL visceral